Whitney Tew
Family Medicine · Huntsville, ALNPI 1205268810
Payments from drug & device makers
Across 665 payments — averaging $171.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$96K
- Novo Nordisk$12K
- AbbVie$2K
- Lilly USA, LLC$555
- Amgen$528
- Boehringer Ingelheim$474
- plus $3K from 30 others
What the payments were for
- Consulting fees$95,83384%
- Speaking & faculty fees$9,7279%
- Travel & lodging$2660%
- Food & beverage$8,3727%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 48 | $95,833 |
| Novo Nordisk | 154 | $12,010 |
| AbbVie(2 entities) | 144 | $1,666 |
| Lilly USA, LLC | 37 | $555 |
| Amgen | 37 | $528 |
| Boehringer Ingelheim | 31 | $474 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $397 |
| Amarin Pharma, Inc. | 26 | $370 |
| AstraZeneca | 21 | $301 |
| Kowa Pharmaceuticals America, Inc. | 22 | $243 |
| Pfizer | 25 | $222 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $220 |
| Merck | 12 | $188 |
| Johnson & Johnson | 10 | $183 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $153 |
| Sanofi-aventis U.S. LLC | 6 | $98 |
| IBSA Pharma Inc. | 5 | $91 |
| Dexcom, Inc. | 5 | $88 |
| GSK | 5 | $74 |
| Vivus LLC | 4 | $67 |
| Ironwood Pharmaceuticals, Inc | 4 | $55 |
| Bayer | 3 | $52 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Abbott | 2 | $29 |
| Nalpropion Pharmaceuticals LLC | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Eisai Inc. | 2 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Biogen | 1 | $20 |
| Shire North American Group Inc | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,197 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $11,568 |
| Gabapentin | 65 | $709 |
| Zolpidem Tartrate | 32 | $202 |
| Tramadol Hcl | 32 | $196 |
| Eszopiclone | 14 | $162 |
| Temazepam | 17 | $89 |
| Clonazepam | 28 | $83 |
| Lorazepam | 16 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $555 | $11,56811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Huntsville
- Michael CarterHuntsville$3.4M
- Randle MiddletonHuntsville$3.3M
- Timothy HowardHuntsville$3M
- Edward WittHuntsville$321K
- Kathleen DupperHuntsville$210K
- Jeffrey GarberHuntsville$87K
- Daniel EnglertHuntsville$82K
- Jack EnglertHuntsville$37K
- Tobin FisherHuntsville$33K
- David ShowersHuntsville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.